
Johnson & Johnson
JNJHealthcare|Drug Manufacturers - General|USA
$240.97
-2.07 (-0.85%)
DCF (FCF)
$109.52
Earnings Power
$76.17
Analyst Ratings
| Firm / Analyst | Rating | Price Target | Date |
|---|---|---|---|
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — |
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812"
],
"revenue_estimate": [
100573.21,
106456.18,
112591.45
],
"ebit_estimate": [
33411.2,
36054.66,
39221.38
],
"ebitda_estimate": [
37938.34,
40497.15,
42772.75
],
"net_income_estimate": [
27915.05,
30239.05,
33082.78
],
"per_share_eps_estimate": [
9.44,
10.15,
11.38
],
"eps_nri_estimate": [
11.54,
12.55,
13.69
],
"dividend_estimate": [
5.28,
5.63,
5.82
],
"book_value_per_share_estimate": [
36.3,
41.83,
49.2
],
"pretax_income_estimate": [
34266.35,
37284.97,
40825.35
],
"operating_cash_flow_per_share_estimate": [
14.15,
13.7,
16.08
],
"roa_estimate": [
13.07,
13.53,
12.9
],
"roe_estimate": [
32.77,
31.83,
30.87
],
"gross_margin_estimate": [
72.68,
72.88,
72.96
],
"operating_cash_flow_estimate": [
34581.05,
33481.61,
39287.88
],
"pettm_estimate": [
25.52,
23.74,
21.17
],
"long_term_growth_rate_mean": 8.32,
"long_term_revenue_growth_rate_mean": "6.10",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": 8.32,
"future_revenue_estimate_growth": 6.1,
"future_ebit_estimate_growth": 5.6,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": 4.48,
"future_net_income_estimate_growth": 7.37,
"future_pretax_income_estimate_growth": 7.91,
"future_book_value_per_share_estimate_growth": 13.45,
"future_roa_estimate_growth": -2.35,
"future_roe_estimate_growth": -4,
"future_gross_margin_estimate_growth": 2.22,
"future_operating_cash_flow_per_share_estimate_growth": 14.61
}
quarterly
{
"date": [
"202603",
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712"
],
"revenue_estimate": [
23623.39,
25074.25,
25339.19,
26609.64,
24520.26,
26392.01,
26787.86,
28567.3
],
"ebit_estimate": [
7865.01,
8462.16,
8645.66,
8389.35,
8367.27,
9004.28,
9208.04,
9415.55
],
"ebitda_estimate": [
9105.6,
9513.96,
9749.32,
9429.7,
9608.1,
10194.81,
10472.53,
10989.28
],
"net_income_estimate": [
6539.35,
6991.29,
7283.12,
7232.09,
7080.11,
7595.47,
7792.23,
7913.98
],
"per_share_eps_estimate": [
2.2,
2.51,
2.63,
2.53,
2.47,
2.74,
2.77,
2.7
],
"eps_nri_estimate": [
2.67,
2.88,
3,
2.98,
2.9,
3.09,
3.16,
3.27
],
"dividend_estimate": [
1.31,
1.31,
1.31,
1.31,
1.35,
1.35,
1.35,
1.35
],
"book_value_per_share_estimate": [
35.41,
36.45,
37.7,
38.89,
40,
41.3,
42.75,
44.33
],
"pretax_income_estimate": [
7929.08,
8554.27,
8948.87,
8753.01,
8609.41,
9237.1,
9475.37,
9701.22
],
"operating_cash_flow_per_share_estimate": [
3.18,
3.33,
3.54,
1.74,
3.47,
3.64,
3.78,
3.79
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
32.43,
33.32,
34.92,
33.18,
32.23,
33.05,
33.4,
32.38
],
"gross_margin_estimate": [
71.92,
73.01,
73.91,
73.18,
72.97,
73.3,
73.6,
73.56
],
"operating_cash_flow_estimate": [
7769.38,
8135.86,
8648.93,
4238.95,
8477.9,
8893.25,
9235.3,
9259.73
],
"pettm_estimate": [
24.44,
23.79,
23.26,
22.94,
22.56,
null,
null,
null
],
"long_term_growth_rate_mean": 8.32,
"long_term_revenue_growth_rate_mean": "6.10",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": 8.32,
"future_revenue_estimate_growth": 6.1,
"future_ebit_estimate_growth": 5.6,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": 4.48,
"future_net_income_estimate_growth": 7.37,
"future_pretax_income_estimate_growth": 7.91,
"future_book_value_per_share_estimate_growth": 13.45,
"future_roa_estimate_growth": -2.35,
"future_roe_estimate_growth": -4,
"future_gross_margin_estimate_growth": 2.22,
"future_operating_cash_flow_per_share_estimate_growth": 14.61
}